Stocks Health care BMY
NYSE · Health careBristol Myers Squibb Co (BMY)
Bristol Myers Squibb Co brought in $49.2B of revenue over the twelve months to June 30, 2026, up 3.1% from a year earlier. Net income was $9.3B, a net margin of 18.9%. Operating cash flow minus capital spending left $12.8B of free cash flow in fiscal 2025. At June 30, 2026 it held $8.7B in cash against $42.9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
Key facts about Bristol Myers Squibb Co
- Net worth
- Bristol Myers Squibb Co has a market value (market cap) of $117.6B at the latest share price, and shareholders' equity of $22.3B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $48.2B (-0.2% year on year), with net income of $7.1B. Over the 12 months to June 30, 2026: revenue $49.2B, net income $9.3B.
- Cash flow
- In fiscal 2025 operations brought in $14.2B of cash; after $1.3B of capital spending, free cash flow was $12.8B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 30, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Bristol Myers Squibb Co's next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Bristol Myers Squibb Co declared dividends of $2.49 per share in fiscal 2025, a yield of 4.32% at the current price.
What Bristol Myers Squibb Co does
Bristol Myers Squibb discovers, develops, and sells biopharmaceutical medicines. The company focuses on therapeutic areas including oncology, hematology, immunology, and cardiovascular diseases. Its prescription drugs, such as Eliquis and Opdivo, are sold to hospitals, clinics, and pharmacies. Its shares trade on NYSE under the ticker BMY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $48.2B | $7.1B | $3.46 | $12.8B |
| 2024 | $48.3B | -$8.9B | -$4.41 | $13.9B |
| 2023 | $45B | $8B | $3.86 | $12.7B |
| 2022 | $46.2B | $6.3B | $2.95 | $11.9B |
| 2021 | $46.4B | $7B | $3.12 | $15.2B |
| 2020 | $42.5B | -$9B | -$3.99 | $13.3B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BMY ranks in Health care
Dividends
Bristol Myers Squibb Co declared $2.49 per share in fiscal 2025. At the current price that is a yield of 4.32%. It paid out $5B in cash dividends, 72% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $2.49 | $5B | 72% |
| 2024 | $2.42 | $4.9B | n/a |
| 2023 | $2.31 | $4.7B | 59% |
| 2022 | $2.19 | $4.6B | 73% |
| 2021 | $2.01 | $4.4B | 63% |
| 2020 | $1.84 | $4.1B | n/a |
Latest SEC filings
What Bristol Myers Squibb Co has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.7% to $13B versus the same quarter last year; diluted EPS $1.62 versus $0.64.
- July 30, 2026
- June 5, 2026
- June 5, 2026
- June 5, 2026
- May 8, 2026
- May 8, 2026
- April 30, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 2.6% to $11.5B versus the same quarter last year; diluted EPS $1.31 versus $1.20.
- April 30, 2026
What is BMY worth? A DCF from its reported cash flow
Insider trades
What the people running Bristol Myers Squibb Co did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $437.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 2, 2026 | Gallman CariEVP, General Counsel | Exercised options | 4,559 | - |
| October 2, 2026 | Gallman CariEVP, General Counsel | Shares withheld for tax | 2,332 | $142.6K |
| September 9, 2026 | Massacesi CristianEVP,Chief Med Offr,Head of Dev | Sold | 6,249 | $403.5K |
| September 1, 2026 | Short Bartie WendyEVP, Corporate Affairs | Exercised options | 1,236 | $82.7K |
| September 1, 2026 | Short Bartie WendyEVP, Corporate Affairs | Shares withheld for tax | 633 | $42.4K |
| August 25, 2026 | Holzer Phil MSVP and Controller | Sold | 500 | $33.8K |
| August 1, 2026 | Gallman CariEVP, General Counsel | Exercised options | 1,061 | - |
| August 1, 2026 | Gallman CariEVP, General Counsel | Shares withheld for tax | 543 | $35.5K |
Who owns BMY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.49% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 2,514 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 180,384,994 | +8,702,106 |
| Vanguard Capital Management LLC | 133,337,856 | +1,017,616 |
| State Street Corp | 102,408,940 | +3,844,026 |
| Jpmorgan Chase & Co | 71,713,442 | -20,761,752 |
| Charles Schwab Investment Management Inc | 67,595,177 | +6,479,804 |
| Geode Capital Management, LLC | 56,443,077 | +1,156,903 |
| Vanguard Portfolio Management LLC | 46,873,015 | +642,860 |
| Norges Bank | 36,866,658 | new |
| Bank of America Corp | 34,045,352 | +1,458,371 |
| Morgan Stanley | 29,009,025 | -189,529 |
| Aqr Capital Management LLC | 27,357,486 | -2,273,619 |
| Ameriprise Financial Inc | 26,670,064 | +199,346 |
| Primecap Management Co | 24,923,900 | -61,249 |
| Northern Trust Corp | 24,918,384 | +159,613 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 22,839,010 | +119,690 |
| Bank of New York Mellon Corp | 21,821,384 | -1,479,953 |
| Independent Franchise Partners LLP | 21,792,841 | +517,367 |
| Dimensional Fund Advisors LP | 19,691,951 | +929,362 |
| Legal & General Group Plc | 17,022,940 | +145,314 |
| Goldman Sachs Group Inc | 17,016,799 | +2,962,281 |
Insiders
14 insiders reported holding 408,407 shares in total, about $23.5M at the last price.
| Holder | Shares |
|---|---|
| Elkins David VEVP, Chief Financial Officer | 159,248 |
| Haller Julia ADirector | 34,079 |
| Meyers Gregory ScottEVP, Chief Digital & Tech Off. | 30,361 |
| Shanahan KarinEVP, Chief Supply Chain & Ops | 25,888 |
| Plenge Robert MEVP, Chief Research Officer | 21,528 |
| Boerner Christopher S.Chief Executive Officer, Director | 21,451 |
| Lenkowsky AdamEVP, Chief Commercial Officer | 19,706 |
| Massacesi CristianEVP,Chief Med Offr,Head of Dev | 18,748 |
| Holzer Phil MSVP and Controller | 16,862 |
| Hickey BenjaminPresident, RayzeBio Org. | 16,672 |
Questions about BMY
What does Bristol Myers Squibb Co do?
Bristol Myers Squibb discovers, develops, and sells biopharmaceutical medicines. The company focuses on therapeutic areas including oncology, hematology, immunology, and cardiovascular diseases. Its prescription drugs, such as Eliquis and Opdivo, are sold to hospitals, clinics, and pharmacies. Its shares trade on NYSE under the ticker BMY.
What is Bristol Myers Squibb Co's net worth?
Bristol Myers Squibb Co has a market value (market cap) of $117.6B at the latest share price, and shareholders' equity of $22.3B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bristol Myers Squibb Co profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $9.3B on revenue of $49.2B, a net margin of 18.9%.
How much revenue does Bristol Myers Squibb Co make?
Over the twelve months to June 30, 2026 Bristol Myers Squibb Co reported revenue of $49.2B. That is 3.1% more than a year earlier.
When did Bristol Myers Squibb Co last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 5, 2026.
When is Bristol Myers Squibb Co's next earnings report?
Bristol Myers Squibb Co's next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Bristol Myers Squibb Co pay a dividend?
Yes. Bristol Myers Squibb Co declared dividends of $2.49 per share in fiscal 2025, a yield of 4.32% at the current price.
Similar companies
Compare BMY with
Follow BMY
Get an email when Bristol Myers Squibb Co files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bristol Myers Squibb Co tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.